Clinical trial
Phase II Trial of EOquin in High-risk Superficial Bladder Cancer
NCT00141531 · Spectrum Pharmaceuticals, Inc, Industry · Completed
Key facts
| NCT number | NCT00141531 |
|---|---|
| Title | Phase II Trial of EOquin in High-risk Superficial Bladder Cancer |
| Official title | Phase II Study of Intravesical Instillation of EOQUIN™ in High Risk Superficial Bladder Cancer |
| Lead sponsor | Spectrum Pharmaceuticals, Inc, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Bladder Neoplasms |
| Intervention type | Drug |
| Interventions | Apaziquone |
| Enrollment | 53 |
| Start date | Jul 1, 2005 |
| Primary completion | Dec 1, 2009 |
| Completion | Dec 1, 2009 |
| First posted | Sep 1, 2005 |
| Last update posted | Jun 14, 2012 |
| Countries | Netherlands |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: